Hooked on rebates?: CNBC UK Exchange newsletter
On September 19, 2024, Keencare Pharmacy, a member of Green Light Group, in London, England, has drug boxes on the shelves.
Leon Neal | Getty Images News | Getty Images
This report is from this week’s CNBC’s UK Stock Exchange Bulletin. Every Wednesday, Ian King brings you expert information about the most important business stories from the UK and other important developments you will not want to miss. As you can see? You can subscribe Here.
Distribution
He was asked to name an industry where England was perfect, many of them would talk about life sciences.
Inside Astrazeneca And GSKThe country has two of the world’s largest 15 pharmaceutical companies – it can match only the US and Switzerland – and in Cambridge, Oxford and Imperial College London, three of the top 10 universities of the world. It is also one of the top five global investments for life science research.
Under the surface, not everything is fine. The relations between the commercial body and the UK pharmaceutical industry, which is less and GSK, contain domestic weapons of multinational companies such as Pfizer, Sanofi, Merck, Eli Lilly and Bristol-Myers Squibb.
Most branded drugs in the UK are purchased by the National Health Service (NHS) operated by the state. Thanks to its size – NHS has a large purchase power – it accounts for about 85% of health expenditures.
This has been supported by voluntary pricing agreements for decades-voluntarily in the sense that non-voluntary terms will be worse between the industry and NHS. The last of these, the pricing of branded drugs, access and growth (VPAG) voluntary scheme entered into force in January last year.
Within the scope of the plan between the NHS, NHS and the British Pharmaceutical Industry Association (ABPI) Association, a limit on how much NHS spends on branded drugs every year. This cover is currently allowed to increase by 2% per year and increases to 4% per year until 2027. To implement the CAP, pharmaceutical companies agree to repay a percentage of drug sales to NHS via a discount or “PlowBack”. In the last 11 years, this discount average is slightly above 10%, but in December last year, the current health state secretary Wes Streeting shocked the industry by setting a rate of 23% – significant ahead of the expected 15%.
British Health Secretary Wes Streeting speaks on March 28, 2025 at the start of the “NHS Action Day ında in Runcorn, England.
Cameron Smith | Getty Images News | Getty Images
The ABPI warned that it would immediately put a “very real coercion on companies” and at risk of England’s industrial growth and investment.
He said that in 9% of the UK’s health expenditures, NHS used a smaller health cost share than any comparable country and spent 15% of France and 17% of Germany and Italy.
The negotiations have been thundered since then, but 12 days ago, AbPI’s lower discount rates in all the future years of the plan and abandoned abandoned talks after rejecting an offer that includes an increase in both the price of new drugs and a net expenditures.
“I will not allow Big Pharma to break down our patients or taxpayers.”
A Life Sciences Super Power?
The danger of streeting, which is seen as a possible successor for Prime Minister Keir Starmer, is that the queue hurts the wider economy.
In July, Pascal Soriot, General Manager, announced that it plans to invest in approximately $ 50 billion to the US (which constitutes 43% of the company’s global sales) until 2030, and called AZ, calling the government and Az, which calls it a “very American company”. The importance of this, according to reports in The Times, Soriot The FTSE-100’s largest company has specially discussed to move the primary list of AZ to New York.
Although it is the biggest name in Pharma, England, it is not the only unhappy industry leader at the Soriot Discount level.
Pfizer’s President of the UK Country John McGinley, an ABPI report, he said. published In March, the unexpected hike in the discount was “incompatible with the desire of the British government to be a global life leader”.
In the same report, Merck’s General Manager of England and Ireland, Doina Ionescu, described the new rate as “inappropriate” and added that “the ability to explore innovative drugs and surrender to patients”.
The latest critic, Johan Kahlström, the General Manager of Novartis, said that the BBC was “largely incredibly incredibly for the drug producers of the UK last week.
Hiding in the background, US President Donald Trump. The President demanded that pharmaceutical companies reduce the drug prices in the United States to comply with those in Europe and Canada. This price difference greatly reflects how the US health system is structured, but it still allowed Trump to claim that they subsidized American patients elsewhere.
Companies like Eli Lilly said that the price paid for drugs by health systems for drug prices to fall into the United States, he said. Last week, weight loss medication Mounjaro temporarily suspended UK shipments before a major price increase this month.
Therefore, Trump’s demands increase the need for drug producers to produce better terms than the British government. By combining the problem, they may not want to accept these terms until Trump obtains more tariffs on pharmaceutical imports, which may have an inflationary effect on the US sales prices, thus making more pressure to raise prices in other places.
The line on the discount may have other unwanted side effects. It gives an excuse to direct drug producers such as AZ to direct research and development expenditures to the US, as Trump requested.
In addition, the probability of launching new drugs in the UK is lower – the criteria used by the Institute of National Health and Care Excellence (NICE) due to another running pain for the industry, the body that decides whether the new drugs represent a good value for NHS.
Everything leaves the United Kingdom government, which promises to make the country a “superpower of life sciences”.
Best TV choices in CNBC
British yields at high levels, Markets Prime Minister Keir Starmer’s economic advisory team intimidates the shaking of the team, while not seen since 1998.
Allen Simpson, CEO of Ukhospitality, is discussing the impact of the increasing taxes of the UK Chancellor Rachel Reeves on the hospitality industry.
Ritika Gupta from CNBC reported that the hospitality sector was hit with tax increases and the closure of London bars.
– Holly Ellyatt
You need to know
Your week’s quote
“The chancellor is absolutely stubborn.
Allen Simpson, CEO, Ukhospitality
In markets
British assets have suffered in recent days because concerns about the country’s financial appearance and debt sustainability have come to the fore. Sterling fell more than 1% against the US dollar on Tuesday as borrowing costs increased on the board. 30 -year -old gilded yield It has reached its highest level since 1998.
. FTSE 100 Meanwhile, he continued to move away from the record levels of August. The blue chip index fell 1.44% last week and has lost 0.44% since September. This is a wider risk of global stocks, with the upright decreases in European stocks and Wall Street.
Financial Times Stock Exchange 100 Index last year’s performance.
Appearance
4 September: England new car sales data
September 5: England retail sales data; HALIFAX HOUSE PRICE INDEX DATA
– Holly Ellyatt
